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Abstract 
Aim 
The aim of this investigation was to estimate separate risks of major lower limb amputation 
and death following revascularisation for peripheral artery disease (PAD) using competing 
risks analysis. 
Methods 
Routinely collected data  from Hospital Episode Statistics (HES) were used to identify 
patients who underwent endovascular or open lower limb revascularisation in England in 
2005-2015. The primary outcomes were major lower limb amputation and death within 5 
years of revascularisation. Cox proportional hazards and Fine-Gray competing risks 
regression were used to examine the competing risks of these outcomes. 
Results 
Some 164 845 patients underwent their first lower limb revascularisation for PAD in 2005-
2015. Most patients were men (64.6%); the median age was 71 years (IQR: 62- 78 years). 
Following endovascular revascularisation, the 5-year cumulative incidence of amputation was 
4.2% in patients with intermittent claudication and 18.0% in those with a record of tissue 
loss. After open revascularisation, the corresponding rates were 10.7% and 25.3% and after 
combined procedures, they were 8.1% and 25.0%. The 5-year cumulative incidence of death 
varied from 24.6% to 40.3%, depending on procedure type.  Competing risks methods 
consistently produced lower estimates than standard methods.  
Conclusion 
Our findings suggest that the 5-year risk of major amputation following lower limb 
revascularisation for PAD is lower than previously estimated. Patients undergoing 
revascularisation for tissue loss and those who need open revascularisation are at highest risk 
of limb loss.   
Comment [U1]: Are the data in the results 
presented above based on competing risk 
models? 
 
Our response: Yes, all result s in the abstract 
are based on compering risks analyses. 
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Introduction 
Peripheral artery disease (PAD), characterised by atherosclerosis in the arteries of the 
extremities, is the third most common cause of morbidity worldwide, after stroke and 
coronary heart disease.
1
 The prevalence of PAD is growing: in 2010, an estimated 61 million 
men and women in high-income countries were living with this disease, representing a 13% 
increase during the preceding decade.
1
 An important treatment goal in PAD is to manage 
blood flow to the limb. Where medical treatment or lifestyle modification have been 
inadequate, endovascular and open revascularisation procedures can be used to improve the 
blood flow. These interventions carry appreciable risks to life and limb.
2, 3
 In the Bypass 
versus Angioplasty for Severe Ischaemia of the Limb (BASIL) study, a multi-centre trial 
conducted in 27 United Kingdom hospitals in 1999-2004, the investigators reported 3-year 
rates of amputation-free survival of 57% among patients randomised to bypass and 52% 
among those randomised to angioplasty. 2 egister-based studies conducted in the United 
States and Sweden between 1996 and 2003 have shown similar findings, with 5-year rates of 
amputation-free survival following leg bypass reported as just under 50%. 4, 5  
 
Previous studies of patient outcomes following lower limb revascularisation have reported on 
death or amputation-free survival (time to death or major lower limb amputation, whichever 
occurs first) 
2-6
. Few investigations have provided information on the risk of amputation 
independently of the risk of death, although this is an important outcome for patients. In 
studies that have reported separate amputation rates, time to amputation has typically been 
derived using standard Kaplan-Meier analysis and Cox proportional hazards regression. 4, 7-9 
These methods are based on the assumption that the risks of multiple outcomes are 
independent, and they will produce biased estimates in the presence of non-independent, 
competing risks 10, 11. The independent risks-assumption is unlikely to be valid in a 
population of patients undergoing revascularisation for PAD. In this group of typically older 
patients with high level of multimorbidity, rates of both death and amputation are relatively 
high, and the rate of amputation is influenced by the rate of death. This is because patients 
who have died are no longer at risk of having an amputation, and the risks of amputation and 
death are therefore not independent of one another. It is thus likely that many previously 
published estimates of the risk of amputation following lower limb revascularisation have 
been overestimated by standard methods, and more accurate estimates are needed. 
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To address this gap in the knowledge, the aim of the current investigation was to examine the 
separate risks of major lower limb amputation and death following endovascular and open 
lower limb revascularisation procedures undertaken in England between January 2005 and 
December 2015, using a competing risks approach 
12
.  
 
Methods 
Data sources 
Individual-level data were used to identify all lower limb revascularisation procedures due to 
PAD recorded in Hospital Episode Statistics (HES), an administrative dataset containing 
information on all hospital admissions in National Health Service (NHS) hospitals in England 
13. Patient HES records include information on procedures, patient characteristics and 
admission details. Medical diagnoses are coded using the International Classification of 
Diseases (ICD, version 10) and procedures using the Office of Population, Census and 
Surveys (OPCS, version 4) codes. In the analyses described here, each patient was identified 
using an anonymised label, which allowed all of his or her admissions data to be linked.  
Patient deaths were ascertained from Office for National Statistics (ONS) records of deaths 
registered in England up to December 2015 
14
.  
 
Study population 
The study population comprised men and women, aged 35 years or older, who underwent 
their first lower limb revascularisation for PAD (index procedure) between 1
st
 January 2005 
and 31st  December 2015. Patients who had a HES record of a lower limb revascularisation 
up to three years prior to the index procedure were excluded. Further excluded were non-UK 
residents, patients whose primary indication for revascularisation was malignant or benign 
neoplastic disease, trauma or congenital malformation, and those with incomplete data on 
covariates (<0.01%). 
 
Revascularisation procedures were grouped into three categories: endovascular 
revascularisation alone, open revascularisation (endarterectomy, profundaplasty or bypass) 
alone, or a combination endovascular and open procedures. Primary and secondary diagnostic 
codes at the index admission were used to identify patients undergoing these procedures for 
PAD. Patients were categorised into groups indicating increasing severity of PAD as follows: 
intermittent claudication (IC: ICD-10 code I73.9 for intermittent claudication), severe limb 
ischaemia without a record of tissue loss (SLI: ICD-10 code(s) I70.2, I72.4, I70.0-8, I74.3-5, 
Page 4 of 29
http://mc.manuscriptcentral.com/bjs
BJS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
FOR REVIEW
 ONLY
5 
 
I77.1 or I77.9 but no code(s) for diabetes with peripheral circulatory complications or tissue 
loss) and severe limb ischaemia with a record tissue loss (TL: code(s) for PAD and code(s) 
indicating tissue loss or diabetes with peripheral circulatory complications).   The OPCS and 
ICD-10 codes used to identify the revascularisation procedures and indications are provided 
in the Online Appendix, Supplementary Tables S1-S3. 
 
The risk estimates were adjusted for patient age, sex and the RCS Charlson score, which was 
derived using primary and secondary diagnostic codes from the index hospital admission as 
well as admissions during the 12 months preceding the index admission.
15
 Acute conditions 
(e.g. myocardial infarction) were included in the number of co-morbidities only if they were 
present in a record of a hospital admission preceding the index admission. (Online Appendix, 
Supplementary Table S4). PAD and diabetes were excluded from the calculation of the 
comorbidity score because these formed part of the inclusion criteria for the study, and all 
patients had a record of at least one of these.  
  
Outcomes 
The primary outcomes were major lower limb (i.e. above the ankle) amputation (ipsilateral or 
contralateral) and death from any cause, on a date later than the date of the revascularisation 
procedure. Amputations due to trauma or neoplastic disease were excluded. Amputation-free 
survival (time from revascularisation procedure to major amputation, death from any cause or 
the end of follow-up, whichever occurred first) was examined as a secondary outcome. OPCS 
codes for identifying major lower limb amputations are provided in Online Appendix, 
Supplementary Table S5.  
 
Statistical analyses 
Patients were followed up from the date of the revascularisation to the date of a subsequent 
major lower-limb amputation, death or the end of follow-up (December 2015), for a 
maximum of 5 years.  The cumulative incidences of major amputation and death, 
independently from one another, were estimated for each type of revascularisation and 
indication for treatment using Fine-Gray competing risks regression models 
12
.  The 
competing risks approach was chosen because in the presence of non-independent, competing 
risks, the cumulative incidence of an outcome (such as major amputation) is influenced by 
the cumulative incidence(s) of competing outcome(s) (such as death) 10, 11.  The Fine-Gray 
model overcomes this problem by producing separate estimates for the cumulative incidence 
Comment [kh2]: Added explanation on how 
HES codes were used to define categories. 
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of the main outcome and the competing outcome.12 Using the competing risks approach, 
amputation-free survival was calculated as one minus the sum of the independent cumulative 
incidences of amputation and death. 
 
Three sensitivity analyses were conducted: the first one used  Kaplan-Meier curves and Cox 
proportional hazards regression 
16
  to illustrate the degree to which the risk of amputation is 
overestimated using standard survival analysis methods, the second one examined the impact 
of not adjusting for the RCS Charlson score in the competing risks models and the third 
investigated the effect of combining SLI and TL as one analytical category. The latter two 
analyses were  done to explore the impact of the quality of coding for secondary diagnoses 
and comorbidities in HES).  
 
Proportional hazards assumption for the Cox models was checked visually, using log-log-
plots (of log-log of the survival function against the logarithm of time) and Schoenfeld test 
(testing for interaction between Schoenfeld residuals and time). In the competing risk models 
the proportionality of sub-distribution hazards was checked by including in the model an 
interaction term with time. The assumptions were reasonably valid for all procedure-outcome 
pairs. Age (ten-year bands from 30 to 80+), sex, the RCS Charlson score (0, 1, 2, 3+), and 
indication for revascularisation (IC, SLI or TL) were modelled as categorical variables. All 
analyses were conducted using Stata MP 14 (Stata Corporation, College Station, Texas, US). 
 
Results 
Between January 2005 and December 2015, some 164 845 men and women underwent their 
first lower limb revascularisation for PAD. Overall, the majority of these patients were men 
(64.6%) and the median age was 72 years (interquartile range, IQR: 62 to 78 years).  The 
most common procedure was endovascular revascularisation alone (n=120 463, 73% of the 
procedures), followed by open revascularisation alone (n=39 824, 24%) and endovascular 
and open procedures together (n=4 558, 3%).   
 
Severe limb ischaemia (SLI) without record of tissue loss was the most common indication 
for endovascular revascularisation, recorded as the underlying aetiology in 55.6% of all 
revascularisation procedures. IC was the indication for 23.9% of the patients in all procedure 
groups and severe limb ischaemia with a record of tissue loss (TL) accounted for 21.6% 
Comment [kh3]: Added a sensitivity 
analysis. 
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(Table 1). Overall, around 86% of patients had at least one comorbidity indicated by the RCS 
Charlson score, and 22% of patients had three or more.  
 
In all, 13 620 patients (8.3%) underwent a major lower limb amputation and 42 570 (25.8%) 
died during the 5 years following lower limb revascularisation. Median follow-up was 3 years 
(IQR: 1 to 5 years). The unadjusted estimates of cumulative incidence of major lower limb 
amputations associated with each type of revascularisation were calculated using the Kaplan-
Meier and Fine-Gray methods (Figure 1). The Kaplan-Meier method consistently produced 
higher estimates of the risk of amputation, particularly towards longer follow-up, 
demonstrating that standard methods tend to overestimate the risk of amputation when the 
competing risk of death is not taken into account in the analyses.  
 
Unadjusted cumulative incidences of amputation and death at 1, 3 and 5 years after 
revascularisation were calculated using competing risks approach (Table 2).  The cumulative 
incidence of major lower limb amputation was higher in patients undergoing open 
revascularisation than in those undergoing endovascular procedures.  It was also notably 
higher in patients who underwent revascularisation for limb ischaemia with a record of tissue 
loss (TL), compared to patients whose indication for revascularisation was intermittent 
claudication (IC) or severe limb ischaemia without a record of tissue loss (SLI) (Table 2). 
The cumulative incidence of death was relatively high in all patient groups.  
 
Amputation-free survival, calculated using competing risks methods, is shown by procedure 
type and indication in Table 3. Amputation-free survival at 5 years varied by procedure type 
and indication: it was the lowest, 26.1%, in those who underwent endovascular 
revascularisation for TL and the highest, 71.1%, in those who had endovascular procedures 
for IC. Amputation-free survival at 5 years following open and combined procedures showed 
similar patterns. Of patients who underwent open or combined revascularisation for TL about 
30% survived, free of major lower limb amputation, at 5 years following revascularisation. 
Of patients who underwent these procedures for IC, some 60%% survived to 5 years without 
a major amputation (Table 3).  
 
Cumulative incidences of amputation and death, adjusted for patient age, sex and RCS 
Charlson score, are shown in Figures 2-4 and Table 4. Overall, the cumulative incidence of 
both outcomes increased sharply over the first year after revascularisation in all procedure 
Comment [U4]: Can you explain to me the 
difference between 
1)SLI 
2)SLI with tissue loss 
3)IC 
The suggestion that 55.2% had SLI 
(presumably) without tissue loss is improbably 
high and not consistent with general clinical 
practice ie most patients with SLI have some 
form of tissue loss (gangrene / ulcer / minor 
amputation). Please clarify. 
 
This will confuse readers and make them 
question the validity of the results.  
 
For comparison please see Mark Nehler and 
Alan Hirsch’s work on CLI at the population 
level – which confirms that most patients with 
CLI have either ulceration / gangrene / tissue 
loss. Fewer have rest pain only. 
J Vasc Surg. 2014;60:686-95 
 
Your data also conflict with German national 
data – published by Holger Reinecke 
Eur Heart J. 2015;36:932-8 
 
Our response: please see our earlier comment 
in this document (last  3 lines of p. 4 and first  
3 lines of p. 5) and also our point-by-point 
response to the Editor’s comments. 
Comment [kh5]: Noted the overall length of 
follow-up here. 
Comment [kh6]: For transparency, we 
propose moving Table 4 (previously table S6) 
from the appendix to the main paper. 
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and indication groups; for the following years, the increase continued, at a steady but lower 
rate. At 5 years post-revascularisation, the adjusted cumulative incidence of amputation was 
the lowest among patients undergoing endovascular procedures for IC (4.2%) and the highest 
among those having open revascularisation for TL (25.3%) (Figures 2-4; Table 4).  
 
When estimated independently from the cumulative incidence of amputation and adjusted for 
patient characteristics, the cumulative incidence of death was relatively high in all patient 
groups: regardless of indication for the intervention, between approximately 25% and 39% of 
patients died within 5 years of the revascularisation procedure. (Figures 2-4; Table 4 
Supplementary Table S6).  
 
The results from the sensitivity analyses exploring the potential impact of the quality of 
diagnostic coding suggest that the main findings of the study are reasonably robust. The 
results from the analyses without adjustment for the RCS Charlson score were nearly 
identical to the main findings (Online Appendix, Figures, S1-S3), reflecting the fact that the 
burden of comorbidity was similar across the indication categories. The risk of amputation in 
the combined SLI+TL group was elevated compared to the SLI group, as might be expected, 
but the difference was relatively modest (Table 2). Similarly, amputation-free survival in the 
SLI+TL group somewhat lower in the SLI group (Table 3). These observations suggest that, 
while misclassification of patients as having SLI only when in reality they also had tissue loss 
(something suggested by the large proportion of patients in the SLI category) would inflate 
the risk estimates for the SLI group, the influence of such bias on the main findings is likely 
to be small. The sensitivity analysis comparing the two analytical approaches demonstrated 
that the risks of both amputation and death estimated using Kaplan-Meier methods were 
higher than those estimated using competing risks methods, particularly among patients with 
a record of tissue loss (Online Appendix, Figures, S1-S3).   
 
Discussion 
Competing risks approach consistently produced lower estimates of the cumulative incidence 
of both outcomes than did standard survival analysis methods, particularly towards the end of 
the 5-year follow up and for patients with the most severe PAD (TL). 
 
Findings from previous studies in England, Sweden and the United States suggest that the 
overall 5-year rates of major lower limb amputation following open and endovascular 
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revascularisation lie between 40% and 50% 2-5.  The findings presented here suggest that the 
risk of amputation following revascularisation for PAD is lower: the highest risks of major 
lower limb amputation, some 25%, were observed in patients undergoing open procedures 
(either alone or in combination with endovascular revascularisation) for the most severe 
underlying disease (TL). By contrast, the 5-year risk of amputation was the lowest among 
patients who underwent endovascular revascularisation for IC or SLI (4% and 7%, 
respectively).  The differences between our observations and those of previous studies are 
likely to relate to standard survival analysis (Kaplan-Meier and Cox) methods overestimating 
the risk of amputation in this patient population where the risks of amputation and death are 
not independent of one another, and where most patients have a high risk of death due to old 
age and multiple comorbidities.  
 
Amputation-free survival at five years from revascularisation, calculated using competing 
risks methods, was between 26% and 71% following endovascular procedures and between 
30% and 60% after open procedures (either alone or in combination with endovascular 
revascularisation).  However, compared to conservative treatment for limb ischaemia, the 
outcomes following endovascular and surgical revascularisation are encouraging. Estimates 
from a recent meta-analysis suggest that at one year of follow-up, over 40% of the patients 
receiving conservative treatment had lost a limb and about 25% had died.
17
 
 
The overall risk estimates can mask meaningful differences in the risks of outcomes between 
patients with different severity of underlying disease. The findings from a longitudinal 
analysis of public health insurance data from over 41 000 German men and women suggest 
that the 4-year risks of amputation and death vary considerably according to disease severity, 
ranging from 4.6% in Rutherford category 1 to 67.3% in Rutherford category 6.9  The 
observations presented here were similar in direction but smaller in magnitude:  the 5-year 
risks of major lower limb amputation varied from approximately 4.2% in patients undergoing 
endovascular revascularisation for IC (the least severe disease) to 25.3% in those undergoing 
open repair for TL (the most severe PAD).  Again, one explanation for the discrepancies in 
the results is likely to be standard survival methods over-estimating risks. However, it must 
be noted that he findings presented here may not be directly comparable to those from other 
countries, because the ICD-10 codes in HES data do not allow a conclusive distinction to be 
made between the categories indicating the severity of PAD. Consequently, the risk estimates 
relating to IC, SLI and TL patients in the present analyses should be taken as indicative of 
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typical risks in these patient groups within England, and not directly used in international 
comparisons. 
 
An important strength of the current investigation is the use of a competing risks approach, 
which allows the estimation of the risks of amputation and death separately from one another, 
thus providing accurate estimates of these risks. Furthermore, the analyses were based on 
prospectively collected individual-patient data on all revascularisations in English NHS 
hospitals in 2005-2015. Therefore, it is unlikely that the findings reported here have been 
biased by sample selection or loss to follow-up. Based on information on just under 165 000 
patients, the analyses likely have sufficient statistical power to provide precise estimates of 
the risk of amputation following endovascular and open revascularisation procedures in 
England.   
 
Despite the strengths of large data, analyses based on administrative hospital data, such as 
HES, are prone to biases arising from incomplete or inaccurate clinical coding. A systematic 
review on the data quality in HES data suggests that the accuracy of diagnostic coding was 
less than satisfactory up to the mid- to late 2000s, but that it has improved since.
18
 However, 
there is evidence that whilst many primary diagnoses and procedures are coded reasonably 
accurately, 
19
 the quality of coding for subsequent diagnoses and procedures varies between 
hospitals.
20
 It is therefore possible that the findings of the current investigation have been 
influenced by differential omission of secondary diagnostic codes and the lack of consistency 
in coding PAD symptoms using ICD-10. To minimise the effect of coding errors, a wide 
range of codes was used to capture as many disease events as possible for the purposes of 
defining the severity of PAD and identifying comorbidities. However, the severity of the 
underlying PAD and the number of comorbidities (which were based on secondary diagnostic 
codes) may have been under-ascertained if coding of secondary diagnoses was incomplete or 
inaccurate. Misclassifying patients to having fewer comorbidities than they in reality had 
could dilute the cumulative incidence estimates by introducing error (statistical “noise”) to 
them. Similarly, misclassifying more severely ill patients into less severely ill categories 
could lead to overestimation of the risks of amputation and death for the less severe 
indication. However, the sensitivity analyses suggest that the potential bias this might have 
introduced to the SLI group was small. Misclassification in covariates would also reduce the 
ability to adjust for these 21. Analyses based on better quality data on patient-level risk factors 
would help to gauge the extent and impact of these potential biases in administrative data. 
Comment [kh7]: Challenges of diagnostic 
coding to define severity of PAD are discussed 
here. 
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It was not possible to reliably ascertain the laterality of the amputations based n HES data, 
and it is thus not known what proportion of the amputations were done on the same leg as the 
revascularisation. However, in terms of providing information that is relevant to patients, this 
is not a major limitation, as patients tend to be concerned about their overall risk of losing a 
limb after revascularisation, rather than specific risks of losing the ipsilateral or contralateral 
limb. 
 
Finally, whilst HES is a rich source of data on hospital admissions and procedures, it does not 
contain data on patient-level physiological or lifestyle factors, which may influence the risk 
of amputation or death following lower limb revascularisation.  For this reason, it was not 
possible to investigate the potential impact of factors such as smoking, control of blood 
pressure or diabetes, or physical activity on the present study’s findings. These are areas to 
target in future research. 
 
The findings of this study support those of previous studies that standard survival analysis 
methods can overestimate the risk of the primary outcome of interest in the presence of a 
competing outcome 
11
. This highlights the importance of using appropriate statistical methods 
to estimate the risk of amputation in the population undergoing revascularisation, as most of 
these patients are at high of death due to old age and multiple comorbidities. Importantly, 
using the appropriate methodology allows accurate detection of variation in clinical 
outcomes, which is needed for planning of healthcare delivery and resource allocation in 
vascular surgery and other areas alike. 
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 Figure legends 
 
Figure 1. Kaplan-Meier and competing risks estimates of cumulative incidence of 
amputation following lower limb revascularisation 
Footnote to figure 1:  K-M: Kaplan-Meier estimates; CR: competing risks estimates. 
 
Figure 2. Risk of amputation and death following endovascular revascularisation, by 
indication 
Footnote to Figure 2: Estimates adjusted for age, sex, and RCS Charlson score. 
 
IC: intermittent claudication; SLI: severe limb ischaemia without record of tissue loss; TL: severe limb 
ischaemia with a record of tissue loss. 
 
Figure 3. Risk of amputation and death following open revascularisation, by indication 
Footnote to Figure 3: Estimates adjusted for age, sex, and RCS Charlson score. 
 
IC: intermittent claudication; SLI: severe limb ischaemia without record of tissue loss; TL: severe limb 
ischaemia with record of tissue loss. 
 
Figure 4. Risk of amputation and death following a combination of endovascular and open 
revascularisation, by indication 
 
Footnote to Figure 4: Estimates adjusted for age, sex, and RCS Charlson score. 
 
IC: intermittent claudication; SLI: severe limb ischaemia without record of tissue loss; TL: severe limb 
ischaemia with a record of tissue loss. 
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Table 1. Characteristics of patients undergoing lower limb revascularisation for peripheral arterial disease (PAD) in 2005-2015 
Procedure N procedures Men 
N (%) 
Age (years) 
Median (IQR) 
Indication
1 N (%) RCS Charlson 
score 
2 
N (%) 
Endovascular 120 463 75 201 (62.4) 71 (62 to 79) IC 26 579 (22.1) 0 17 305 (14.4) 
    SLI 67 416 (56.0) 1 67 208 (55.8) 
    TL 26 468 (22.0) 2 10 394 (8.6) 
      3+ 25 556 (21.2) 
    SLI+TL 93 884 (78.0)   
        
Open 39 824 28 076 (70.5) 70 (62 to 78) IC 10 145 (25.5) 0 5 736 (14.4) 
    SLI 21 580 (54.2) 1 20 778 (52.2) 
    TL 8 099 (20.3) 2 3 895 (9.8) 
      3+ 9 415 (23.6) 
    SLI+TL 29 679 (74.5)   
        
Endovascular 4 558 3 231 (70.9) 70 (64 to 77) IC 966 (21.20 0 4 97 (10.9) 
and open    SLI 2 605 (57.2) 1 2 392 (52.5) 
    TL 987 (21.7) 2 421 (9.2) 
      3+ 1 248 (27.4) 
    SLI+TL 3 592 (78.9)   
1 
IC: intermittent claudication; SLI: severe limb ischaemia without record of tissue loss; TL: severe limb ischaemia with record of tissue loss. 
2 Number of comorbidities: details provided in Online Appendix, Supplementary Table S4. 
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Table 2.  Unadjusted cumulative incidence of major amputation and death after lower limb revascularisation, by procedure and 
indication 
   Cumulative incidence of 
amputation (%)  
 Cumulative incidence of death 
(%)  
Procedure Indication 
1 
N (%)
 
Amputation Years of follow-up Death Years of follow-up 
 
 
 N (%) 1 3 5 N (%) 1 3 5 
Endovascular IC 26 579 1 051 (4.0) 2.8 3.7 4.2 5 641 921.2) 7.6 16.5 24.7 
 SLI 67 416  3 067 (4.6) 4.6 6.0 6.9 14 066 (20.9) 10.0 21.4 31.5 
 TL 26 468  4 004 (15.1) 12.6 16.5 18.7 11 012 (41.6) 20.1 39.9 55.2 
           
 SLI+TL 93 884 7 071 (7.5) 5.6 7.4 8.4 25 078 (26.7) 11.2 23.2 33.7 
           
 All 120 463 8 122 (6.7) 4.2 5.6 6.4 30 719 (25.5) 9.8 20.8 30.7 
           
Open IC 10 145 1 013 (10.0) 7.1 9.4 10.6 2 615 (25.8) 10.8 20.4 29.2 
 SLI 21 580 2 196 (10.2) 9.0 12.0 13.5 5 189 (24.1) 12.2 22.8 32.4 
 TL 8 099 1 835 (22.7) 17.6 22.9 25.6 2 958 (36.5) 17.8 32.3 44.6 
           
 SLI+TL 29 679 4 031(13.6) 10.1 13.4 15.0 8 147 (27.5) 12.8 23.8 33.7 
           
 All 39 824 5 044 (12.7) 8.8 11.6 13.1 10 762 (27.0) 12.1 22.6 32.2 
           
Endovascular  IC 966 72 (7.5) 5.3 7.2 8.3 244 (25.3) 10.8 21.6 31.9 
and open SLI 2 605 176 (6.8) 6.7 9.2 10.4 528 (20.3) 11.1 22.2 32.7 
 TL 987 206 (20.9) 16.3 21.9 24.7 317 (32.1) 16.3 31.5 45.0 
           
 SLI+TL 3 592 382 (10.6) 8.3 11.3 12.8 845 (23.5) 12.0 23.6 34.6 
           
 All 4 558 454 (10.0) 6.8 9.2 10.5 1 089 (23.9) 11.5 22.8 33.6 
1 IC: intermittent claudication; SLI: severe limb ischaemia without record of tissue loss; TL: severe limb ischaemia with record of tissue loss.  
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Table 3.  Unadjusted cumulative incidence of composite outcome and amputation-free survival, by procedure and indication 
   Amputation Cumulative incidence of composite 
outcome (%) 
2, 3
 
Amputation-free survival (%)  
2,3 
 
Procedure Indication
1 
N procedures N (%) 1 year 3 years 5 years 1 year 3 years 5 years 
Endovascular IC 26 579 1 051 (4.0) 10.4 20.2 28.9 89.6 79.8 71.1 
 SLI 67 416  3 067 (4.6) 14.6 27.4 38.4 85.4 72.6 61.6 
 TL 26 468  4 004 (15.1) 32.7 56.4 73.9 67.3 43.6 26.1 
          
 SLI+TL 93 884 7 071 (7.5) 16.8 30.6 42.1 83.2 69.4 57.9 
          
 All 120 463 8 122 (6.7) 14 26.4 37.1 86.0 73.6 62.9 
          
Open IC 10 145 1 013 (10.0) 17.9 29.8 39.8 82.1 70.2 60.2 
 SLI 21 580 2 196 (10.2) 21.2 34.8 45.9 78.8 65.2 54.1 
 TL 8 099 1 835 (22.7) 35.4 55.2 70.2 64.6 44.8 29.8 
          
 SLI+TL 29 679 4 031(13.6) 22.9 37.2 48.7 77.1 62.8 51.3 
          
 All 39 824 5 044 (12.7) 20.9 34.2 45.3 79.1 65.8 54.7 
          
Endovascular  IC 966 72 (7.5) 16.1 28.8 40.2 83.9 71.2 59.8 
and open SLI 2 605 176 (6.8) 17.8 31.4 43.1 82.2 68.6 56.9 
 TL 987 206 (20.9) 32.6 53.4 69.7 67.4 46.6 30.3 
          
 SLI+TL 3 592 382 (10.6) 20.3 34.9 47.4 79.7 65.1 52.6 
          
 All 4 558 454 (10.0) 18.3 32.0 44.1 81.7 68.0 55.9 
1 IC: intermittent claudication; SLI: severe limb ischaemia without record of tissue loss; TL: severe limb ischaemia with a record of tissue loss. 
2 
Amputation or death, whichever occurred first. 
3 Unadjusted estimates. 
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Table 4.  Multivariable-adjusted cumulative incidence of major amputation and death after lower limb revascularisation, by procedure 
and indication 
   Cumulative incidence of amputation 
(%) 
1
 
 Cumulative incidence of death 
(%) 
1
 
  Amputation Years of follow-up Death Years of follow-up 
Procedure Indication N (%) N (%) 1 3 5 N (%) 1 3 5 
Endovascular IC 26 579 1 051 (4.0) 2.8 3.7 4.2 5 641 921.2) 7.0 15.7 24.5 
 SLI 67 416  3 067 (4.6) 4.3 5.7 6.5 14 066 (20.9) 8.0 17.9 27.6 
 TL 26 468  4 004 (15.1) 12.1 15.9 18.0 11 012 (41.6) 12.3 26.6 39.8 
           
 SLI+TL 93 884 7 071 (7.5) 5.3 7.0 8.0 25 078 (26.7) 8.5 18.8 28.7 
           
 All 120 463 8 122 (6.7) 4.1 5.4 6.1 30 719 (25.5) 8.0 17.8 27.5 
           
Open IC 10 145 1 013 (10.0) 7.2 9.6 10.8 2 615 (25.8) 9.8 19.1 28.2 
 SLI 21 580 2 196 (10.2) 8.8 11.7 13.2 5 189 (24.1) 10.0 19.5 28.7 
 TL 8 099 1 835 (22.7) 17.3 22.6 25.3 2 958 (36.5) 12.5 24.2 35.0 
           
 SLI+TL 29 679 4 031(13.6) 10.0 13.2 14.8 8 147 (27.5) 10.3 20.2 29.6 
           
 All 39 824 5 044 (12.7) 8.7 11.6 13.0 10 762 (27.0) 10.1 19.8 29.1 
           
Endovascular  IC 966 72 (7.5) 5.2 7.1 8.1 244 (25.3) 10.0 20.5 31.4 
and open SLI 2 605 176 (6.8) 6.5 8.8 10.1 528 (20.3) 9.5 19.6 30.1 
 TL 987 206 (20.9) 16.5 22.2 25.0 317 (32.1) 12.2 24.9 37.4 
           
 SLI+TL 3 592 382 (10.6) 8.1 11.0 12.5 845 (23.5) 10.1 20.7 31.6 
           
 All 4 558 454 (10.0) 6.6 6.0 10.3 1 089 (23.9) 10.1 19.8 29.1 
1 
Estimates adjusted for patient age, sex and RCS Charlson score. 
IC: intermittent claudication; SLI: severe limb ischaemia without record tissue loss; TL: severe limb ischaemia with a record tissue loss. 
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Figure 1. Kaplan-Meier and competing risks estimates of cumulative incidence of amputation following lower 
limb revascularisation  
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Figure 2. Risk of amputation and death following endovascular revascularisation, by indication  
 
242x176mm (72 x 72 DPI)  
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Figure 3. Risk of amputation and death following open revascularisation, by indication  
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Figure 4. Risk of amputation and death following a combination of endovascular and open revascularisation, 
by indication  
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Online Appendix. Supplementary Tables and Figures 
 
Supplementary Table S1. Office of Population Censuses and Surveys Classification of 
Surgical Operations and Procedures (OPCS) version 4.6 codes used to identify open 
revascularisation  
Code Description 
L50.1 Emergency bypass of common iliac artery by anastomosis of aorta to common iliac 
artery NEC 
L50.2 Emergency bypass of iliac artery by anastomosis of aorta to external iliac artery NEC 
L50.3 Emergency bypass of artery of leg by anastomosis of aorta to common femoral artery 
NEC 
L50.4 Emergency bypass of artery of leg by anastomosis of aorta to deep femoral artery 
NEC 
L50.5 Emergency bypass of iliac artery by anastomosis of iliac artery to iliac artery NEC 
L50.6 Emergency bypass of artery of leg by anastomosis of iliac artery to femoral artery 
NEC 
L50.8 Other specified other emergency bypass of iliac artery 
L50.9 Unspecified other emergency bypass of iliac artery 
L51.1 Bypass of common iliac artery by anastomosis of aorta to common iliac artery NEC 
L51.2 Bypass of iliac artery by anastomosis of aorta to external iliac artery NEC 
L51.3 Bypass of artery of leg by anastomosis of aorta to common femoral artery NEC 
L51.4 Bypass of artery of leg by anastomosis of aorta to deep femoral artery NEC 
L51.5 Bypass of iliac artery by anastomosis of iliac artery to iliac artery NEC 
L51.6 Bypass of artery of leg by anastomosis of iliac artery to femoral artery NEC 
L51.8 Other specified other bypass of iliac artery 
L51.9 Unspecified other bypass of iliac artery 
L58.1 Emergency bypass of femoral artery by anastomosis of femoral artery to femoral 
artery NEC 
L58.2 Emergency bypass of femoral artery by anastomosis of femoral artery to popliteal 
artery using prosthesis NEC 
L58.3 Emergency bypass of femoral artery by anastomosis of femoral artery to popliteal 
artery using vein graft NEC 
L58.4 Emergency bypass of femoral artery by anastomosis of femoral artery to tibial artery 
using prosthesis NEC 
L58.5 Emergency bypass of femoral artery by anastomosis of femoral artery to tibial artery 
using vein graft NEC 
L58.6 Emergency bypass of femoral artery by anastomosis of femoral artery to peroneal 
artery using prosthesis NEC 
L58.7 Emergency bypass of femoral artery by anastomosis of femoral artery to peroneal 
artery using vein graft NEC 
L58.8 Other specified other emergency bypass of femoral artery 
L58.9 Unspecified other emergency bypass of femoral artery 
L59.1 Bypass of femoral artery by anastomosis of femoral artery to femoral artery NEC 
L59.2 Bypass of femoral artery by anastomosis of femoral artery to popliteal artery using 
prosthesis NEC 
L59.3 Bypass of femoral artery by anastomosis of femoral artery to popliteal artery using 
vein graft NEC 
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Supplementary Table S1, continued. 
L59.4 Bypass of femoral artery by anastomosis of femoral artery to tibial artery using 
prosthesis NEC 
L59.5 Bypass of femoral artery by anastomosis of femoral artery to tibial artery using vein 
graft NEC 
L59.6 Bypass of femoral artery by anastomosis of femoral artery to peroneal artery using 
prosthesis NEC 
L59.7 Bypass of femoral artery by anastomosis of femoral artery to peroneal artery using 
vein graft NEC 
L59.8 Other specified other bypass of femoral artery 
L59.9 Unspecified other bypass of femoral artery 
L60.1 Endarterectomy of femoral artery and patch repair of femoral artery 
L60.2 Endarterectomy of femoral artery NEC 
L60.3 Profundaplasty of femoral artery and patch repair of deep femoral artery 
L60.4 Profundaplasty of femoral artery NEC 
L60.8 Other specified reconstruction of femoral artery 
L60.9 Unspecified reconstruction of femoral artery 
NEC: not elsewhere classified 
 
 
Supplementary Table S2. OPCS version 4.6 codes used to identify endovascular 
revascularisation 
Code Description 
L54.1 Percutaneous transluminal angioplasty of iliac artery 
L54.4 Percutaneous transluminal insertion of stent into iliac artery 
L63.1 Percutaneous transluminal angioplasty of femoral artery 
L63.5 Percutaneous transluminal insertion of stent into femoral artery 
L66.2 Percutaneous transluminal stent reconstruction of artery 
L66.5 Percutaneous transluminal balloon angioplasty of artery 
L66.7 Percutaneous transluminal placement of peripheral stent in artery 
 
 
Supplementary Table S3. ICD-10 codes to identify indications for revascularisation 
Disease ICD-10 codes 
Intermittent claudication I73.9 
Severe limb ischaemia I70.2, I72.4, I73.0-8, I74.3-5, I77.1, I77.9 
Diabetes with peripheral 
circulatory complications 
E10.5, E11.5, E14.5 
Ulceration L97.X, L03.0, L98.4 
Gangrene R02.X 
Osteomyelitis M86.6, M86.9 
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Supplementary Table S4. ICD-10 codes to identify co-morbidities included in the RCS 
Charlson score (from diagnosis codes in the record of the index admission and previous 
admissions) 
Co-morbidity ICD-10 codes 
Myocardial infarction I21*, I22*, I23*, I252 
Congestive cardiac failure I11, I13, I255, I42, I43, I50, I517 
Cerebrovascular disease G45, G46, I60±I69 
Dementia A810, F00±F03, F051, G30, G31 
Chronic pulmonary disease I26, I27, J40±J45, J46*, J47, J60±J67, J684, J701, J703 
Rheumatological disease  M05, M06, M09, M120, M315, M32±M36 
Liver disease B18, I85, I864, I982, K70, K71, K721, K729, K76, R162, Z944 
Hemiplegia or paraplegia G114, G81±G83 
Renal disease I12, I13, N01, N03, N05, N07, N08, N171*, N172*, N18, N19*, 
N25, Z49, Z940, Z992 
Any malignancy C00±C26, C30±C34, C37±C41, C43, C45±C58, C60±C76, 
C80±C85, C88, C90±C97 
Metastatic solid tumour  C77±C79 
AIDS/HIV infection  B20±B24 
*Acute conditions that were defined as co-morbidities if present in a record of a previous 
hospital admission within 12 months prior to revascularisation.  
AIDS: acquired immune deficiency syndrome; HIV: human immunodeficiency virus. 
 
 
 
Supplementary Table S5. OPCS 4.6 codes to identify major lower limb amputations 
Code Description 
X09.1 Hindquarter amputation 
X09.2 Disarticulation of hip 
X09.3 Amputation of leg above knee 
X09.4 Amputation of leg through knee 
X09.5 Amputation of leg below knee 
X09.8 Other specified amputation of leg 
X09.9 Unspecified amputation of leg 
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Supplementary Figure S1. Minimum-adjusted1 risks of amputation and death following 
endovascular revascularisation, by indication 
 
 
 
 
1 Adjusted for age and sex. 
K-M: Kaplan-Meier estimates; F-G: Fine-Gray estimates.  
IC: intermittent claudication; SLI: severe limb ischaemia without record tissue loss; TL: 
severe limb ischaemia with a record tissue loss. 
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Supplementary Figure S2. Minimum-adjusted1 risks of amputation and death following 
open revascularisation, by indication 
 
 
 
1 Adjusted for age and sex. 
K-M: Kaplan-Meier estimates; F-G: Fine-Gray estimates.  
IC: intermittent claudication; SLI: severe limb ischaemia without record tissue loss; TL: 
severe limb ischaemia with a record tissue loss. 
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Supplementary Figure S3. Minimum-adjusted1 risks of amputation and death following 
a combination of endovascular and open revascularisation, by indication 
 
 
 
 
1 Adjusted for age and sex. 
 
K-M: Kaplan-Meier estimates; F-G: Fine-Gray estimates 
IC: intermittent claudication; SLI: severe limb ischaemia without record tissue loss; TL: 
severe limb ischaemia with a record tissue loss. 
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